Benitec burning cash, looking for licenses
Thursday, 29 July, 2004
Brisbane-based Benitec (ASX: BLT) has announced a loss of AUD$1.9 million for the quarter, and confirmed that it has just $4.65 million remaining in cash.
Company secretary Gary Taylor said that cash burn for the year to date was $8.8 million, but said the company expected to bank $3-4 million in licensing revenues in the next year, including a six-figure sum from the non-exclusive research licence it granted to Merck earlier this month.
The license gave Merck permission to use Benitec’s DNA-directed RNAi (ddRNAi) technology in research activities. At the time, CEO John McKinley said the licence was the first in what he hopes will be a series of research agreements to be announced over the next 12 months.
Benitec has also neatened its corporate structure, buying back the rights to a joint venture company -- the Australian Biotechnology Joint Venture No 1 -- it had used as a tax-effective vehicle for investment in its earlier incarnation, AgGene Australia.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
